ECP treatment of cGVHD: previously reported response rates
. | . | Time since transplantation medians, mo . | . | . | Clinical response . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|
| Authors . | n . | . | Psoralen type . | Treatment frequency . | Skin . | Liver . | Lung . | ||
| Present study | 28 | 34 | Uvadex to Buffy coat | 2 × 2 weekly for 4 months then 2 × monthly | n = 21 | n = 25 | n = 9 | ||
| 1 CR | 0 CR | 0 CR | |||||||
| 9 PR | 8 PR | 0 PR | |||||||
| Smith et al16 | 18 | 36 | Oral 8-MOP | Variable from 2-3 × weekly to 2 × 3 weekly | n = 11 | n = 13 | n = 2 | ||
| Intervals increased if response | 1 CR | 2 CR | 0 CR | ||||||
| 2 PR | 1 PR | 0 PR | |||||||
| Greinix et al17 | 15 | 15 | Uvadex to Buffy coat | 2 × 3 weekly for 3 months then 2 × monthly | n = 15 | n = 9 | — | ||
| 12 CR | 7 CR | ||||||||
| 3 PR | 2 PR | ||||||||
| Salvaneschi et al20 | 14 (pd) | 17 | 8-MOP to Buffy coat | 2 × 2 weekly for 3 months then 2 × 3 weekly | n = 12 | n = 9 | — | ||
| 5 CR | 3 CR | ||||||||
| 5 PR | 3 PR | ||||||||
| Alcindor et al24 | 10 | 18 | Oral 8-MOP | 2 × 2 weekly | n = 10 | n = 3 | — | ||
| 7 PR | 2 PR | ||||||||
| Rossetti et al14 | 8 | 20 | Uvadex to Buffy coat | 2 × 3 weekly for first 6 months | n = 7 | n = 2 | n = 5 | ||
| Intervals increased if response | 2 CR | 1 PR | 1 CR | ||||||
| 2 PR | 1 PR | ||||||||
| Besnier et al21 | 5 | > 36 | 8-MOP to Buffy coat | 3 × weekly for 3 weeks | n = 2 | n = 2 | n = 1 | ||
| Intervals increased if response | 2 PR | 1 PR | 1 PR | ||||||
| Child et al19 * | 6 | 7 | Uvadex to Buffy coat | 2 × 2 weekly for 4 months then 2 × monthly | n = 6 | n = 3 | n = 4 | ||
| 1 CR | 1 PR | 2 PR | |||||||
| 6 PR | |||||||||
| Dippel et al18 | 4 | 34 | Oral 8-MOP | 2 × 4 weekly | n = 4 | — | — | ||
| 1 CR | |||||||||
| 2 PR | |||||||||
| Dall' Amico et al15 | 4 (pd) | 16 | Uvadex to Buffy coat | 2 × 3 weekly for 6 months | n = 3 | n = 1 | n = 2 | ||
| Intervals increased if response | 1 CR | 1 PR | 1 CR | ||||||
| 2 PR | 1 PR | ||||||||
| Rossetti et al22 | 1 (pd) | > 9 | Uvadex to Buffy coat | 2 × 4 weekly for 15 months | n = 1 | — | n = 1 | ||
| 1 PR | 1 PR | ||||||||
| Konstantinow et al23 | 1 (pd) | 24 | 8-MOP to Buffy coat | 2 × 2 weekly for 4 months then 2 × 4-7 weekly | n = 1 | n = 1 | — | ||
| 1 CR | 1 CR | ||||||||
| Owsianowski et al13 | 1 | 60 | Oral 8-MOP | 2 × monthly | n = 1 | n = 1 | — | ||
| 1 PR | 1 PR | ||||||||
| Total (%) | 115; 95 adults, 20 pd | n = 94 | n = 69 | n = 24 | |||||
| 25 (27) CR | 13 (19) CR | 2 (8) CR | |||||||
| 42 (45) PR | 21 (30) PR | 6 (25) PR | |||||||
. | . | Time since transplantation medians, mo . | . | . | Clinical response . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|
| Authors . | n . | . | Psoralen type . | Treatment frequency . | Skin . | Liver . | Lung . | ||
| Present study | 28 | 34 | Uvadex to Buffy coat | 2 × 2 weekly for 4 months then 2 × monthly | n = 21 | n = 25 | n = 9 | ||
| 1 CR | 0 CR | 0 CR | |||||||
| 9 PR | 8 PR | 0 PR | |||||||
| Smith et al16 | 18 | 36 | Oral 8-MOP | Variable from 2-3 × weekly to 2 × 3 weekly | n = 11 | n = 13 | n = 2 | ||
| Intervals increased if response | 1 CR | 2 CR | 0 CR | ||||||
| 2 PR | 1 PR | 0 PR | |||||||
| Greinix et al17 | 15 | 15 | Uvadex to Buffy coat | 2 × 3 weekly for 3 months then 2 × monthly | n = 15 | n = 9 | — | ||
| 12 CR | 7 CR | ||||||||
| 3 PR | 2 PR | ||||||||
| Salvaneschi et al20 | 14 (pd) | 17 | 8-MOP to Buffy coat | 2 × 2 weekly for 3 months then 2 × 3 weekly | n = 12 | n = 9 | — | ||
| 5 CR | 3 CR | ||||||||
| 5 PR | 3 PR | ||||||||
| Alcindor et al24 | 10 | 18 | Oral 8-MOP | 2 × 2 weekly | n = 10 | n = 3 | — | ||
| 7 PR | 2 PR | ||||||||
| Rossetti et al14 | 8 | 20 | Uvadex to Buffy coat | 2 × 3 weekly for first 6 months | n = 7 | n = 2 | n = 5 | ||
| Intervals increased if response | 2 CR | 1 PR | 1 CR | ||||||
| 2 PR | 1 PR | ||||||||
| Besnier et al21 | 5 | > 36 | 8-MOP to Buffy coat | 3 × weekly for 3 weeks | n = 2 | n = 2 | n = 1 | ||
| Intervals increased if response | 2 PR | 1 PR | 1 PR | ||||||
| Child et al19 * | 6 | 7 | Uvadex to Buffy coat | 2 × 2 weekly for 4 months then 2 × monthly | n = 6 | n = 3 | n = 4 | ||
| 1 CR | 1 PR | 2 PR | |||||||
| 6 PR | |||||||||
| Dippel et al18 | 4 | 34 | Oral 8-MOP | 2 × 4 weekly | n = 4 | — | — | ||
| 1 CR | |||||||||
| 2 PR | |||||||||
| Dall' Amico et al15 | 4 (pd) | 16 | Uvadex to Buffy coat | 2 × 3 weekly for 6 months | n = 3 | n = 1 | n = 2 | ||
| Intervals increased if response | 1 CR | 1 PR | 1 CR | ||||||
| 2 PR | 1 PR | ||||||||
| Rossetti et al22 | 1 (pd) | > 9 | Uvadex to Buffy coat | 2 × 4 weekly for 15 months | n = 1 | — | n = 1 | ||
| 1 PR | 1 PR | ||||||||
| Konstantinow et al23 | 1 (pd) | 24 | 8-MOP to Buffy coat | 2 × 2 weekly for 4 months then 2 × 4-7 weekly | n = 1 | n = 1 | — | ||
| 1 CR | 1 CR | ||||||||
| Owsianowski et al13 | 1 | 60 | Oral 8-MOP | 2 × monthly | n = 1 | n = 1 | — | ||
| 1 PR | 1 PR | ||||||||
| Total (%) | 115; 95 adults, 20 pd | n = 94 | n = 69 | n = 24 | |||||
| 25 (27) CR | 13 (19) CR | 2 (8) CR | |||||||
| 42 (45) PR | 21 (30) PR | 6 (25) PR | |||||||
CR indicates complete response; PR, partial response; —, no patients reported; and pd, pediatric cases.
Excludes preliminary data from 5 patients to avoid duplication with present study.